PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
663.07%
Net income growth above 1.5x VET's 27.70%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
7.20%
D&A growth well above VET's 4.86%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
825.00%
Well above VET's 213.20% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-83.33%
Both cut yoy SBC, with VET at -70.44%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
138.44%
Less working capital growth vs. VET's 292.41%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
67.66%
AR growth of 67.66% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
57.13%
AP growth of 57.13% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
112.14%
Lower 'other working capital' growth vs. VET's 292.41%. David Dodd would see fewer unexpected short-term demands on cash.
-97.64%
Both negative yoy, with VET at -3107.01%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
96.20%
Operating cash flow growth above 1.5x VET's 55.51%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-13.30%
Both yoy lines negative, with VET at -32.58%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
78.57%
Some acquisitions while VET is negative at -7316.57%. John Neff sees competitor possibly pausing M&A or divesting while the firm invests in new deals.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91.67%
We reduce yoy other investing while VET is 190.95%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-23.26%
Both yoy lines negative, with VET at -455.27%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-1478.57%
Both yoy lines negative, with VET at -77.54%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
-90.14%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.